iDEL Therapeutics

iDEL Therapeutics is advancing the development of a new generation of anticancer drugs by delivering therapeutic payloads directly into the cytoplasm of tumor cells through a unique uptake mechanism applicable to multiple cancers. Leveraging our synthetic shuttle platform, we are committed to targeting previously inaccessible intracellular targets, broadening the therapeutic window, and providing more treatment options for patients across various indications. The company is dedicated to advancing its pipeline projects into clinical stages while creating scalable value through strategic collaborations.